title: Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".
abstract: "T-body" or chimeric antigen receptor (CAR) technology, which combines the specificity of an antibody with the homing, tissue penetration, and target cell destruction of T cells, was first described in 1993. After many years of unmet promise, significant improvements in gene transfer, including the development of efficient retroviral vectors for transduction of human T cells, and better understanding of immunological pathways and immune cell interactions, are allowing this technology to reach a critical phase of evaluation, in which we will learn whether the approach can truly meet expectations. In this review we summarize the concept of CAR-based immunotherapy, describe the steps accomplished, and outline the future progress we need to make if this approach is truly to improve cancer immunotherapy.
authors.affiliation: Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital, Houston, TX 77030, USA.
authors.forename: Gianpietro
authors.initials: G
authors.lastname: Dotti
authors.forename: Barbara
authors.initials: B
authors.lastname: Savoldo
authors.forename: Malcolm
authors.initials: M
authors.lastname: Brenner
mesh_terms: D018014:Gene Transfer Techniques / Q000639:trends; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D016086:Lentivirus; D018448:Models, Immunological; D011946:Receptors, Antigen / Q000235:genetics*; D011993:Recombinant Fusion Proteins / Q000235:genetics*; D012190:Retroviridae; D013601:T-Lymphocytes / Q000276:immunology; D019139:Tumor Escape / Q000235:genetics* / Q000276:immunology
chemical_list: D011946:Receptors, Antigen; D011993:Recombinant Fusion Proteins
references.citation: Blood. 2005 Jun 1;105(11):4247-54
references.pmid: 15728125
references.citation: Annu Rev Immunol. 2006;24:657-79
references.pmid: 16551262
references.citation: J Clin Invest. 2003 Oct;112(7):1095-107
references.pmid: 14523046
references.citation: Mol Ther. 2007 Jan;15(1):139-45
references.pmid: 17164785
references.citation: Hum Gene Ther. 2002 Nov 1;13(16):1971-80
references.pmid: 12427307
references.citation: J Exp Med. 2005 Oct 3;202(7):907-12
references.pmid: 16203864
references.citation: J Clin Invest. 2008 Sep;118(9):3132-42
references.pmid: 18688285
references.citation: Cancer Res. 2006 Nov 15;66(22):10995-1004
references.pmid: 17108138
references.citation: J Clin Oncol. 2005 Apr 1;23(10):2346-57
references.pmid: 15800326
references.citation: Science. 1997 Jun 13;276(5319):1719-24
references.pmid: 9180086
references.citation: Blood. 2000 Aug 1;96(3):785-93
references.pmid: 10910888
references.citation: Blood. 1998 Sep 1;92(5):1549-55
references.pmid: 9716582
references.citation: J Exp Med. 2008 Jul 7;205(7):1701-14
references.pmid: 18573906
references.citation: Nat Med. 2008 Nov;14(11):1264-70
references.pmid: 18978797
references.citation: Mol Ther. 2009 Aug;17(8):1453-64
references.pmid: 19384291
references.citation: Pharmacol Rev. 2000 Dec;52(4):493-511
references.pmid: 11121508
references.citation: Blood. 2002 Mar 15;99(6):2009-16
references.pmid: 11877273
references.citation: Nat Rev Cancer. 2003 Sep;3(9):666-75
references.pmid: 12951585
references.citation: Expert Opin Biol Ther. 2008 Sep;8(9):1295-307
references.pmid: 18694350
references.citation: Curr Opin Immunol. 2009 Apr;21(2):215-23
references.pmid: 19327974
references.citation: Hum Gene Ther. 2008 May;19(5):511-21
references.pmid: 18471037
references.citation: Semin Immunol. 2009 Apr;21(2):69-77
references.pmid: 19268606
references.citation: J Clin Invest. 2008 Mar;118(3):1027-39
references.pmid: 18246202
references.citation: J Virol. 2003 Jul;77(13):7401-10
references.pmid: 12805439
references.citation: J Immunol. 2004 Dec 15;173(12):7125-30
references.pmid: 15585832
references.citation: Nat Biotechnol. 2002 Jan;20(1):70-5
references.pmid: 11753365
references.citation: Nat Rev Cancer. 2008 Apr;8(4):299-308
references.pmid: 18354418
references.citation: Blood Cells Mol Dis. 2008 Jan-Feb;40(1):84-90
references.pmid: 17964828
references.citation: Blood. 2008 Sep 15;112(6):2261-71
references.pmid: 18509084
references.citation: Blood. 2005 Jun 15;105(12):4677-84
references.pmid: 15713795
references.citation: Blood. 2007 Oct 15;110(8):2793-802
references.pmid: 17638856
references.citation: Br J Haematol. 2004 Aug;126(4):583-92
references.pmid: 15287953
references.citation: Nat Rev Cancer. 2005 Apr;5(4):263-74
references.pmid: 15776005
references.citation: J Exp Med. 2004 Dec 20;200(12):1623-33
references.pmid: 15611290
references.citation: J Pediatr Hematol Oncol. 2007 Oct;29(10):669-77
references.pmid: 17921847
references.citation: Science. 1996 Apr 12;272(5259):263-7
references.pmid: 8602510
references.citation: Leukemia. 2006 Oct;20(10):1819-28
references.pmid: 16932339
references.citation: J Immunother. 2006 May-Jun;29(3):313-9
references.pmid: 16699374
references.citation: Ann Oncol. 1998;9 Suppl 5:S21-4
references.pmid: 9926233
references.citation: Cytotherapy. 2003;5(2):131-8
references.pmid: 12745575
references.citation: Blood. 2002 May 1;99(9):3179-87
references.pmid: 11964281
references.citation: Nat Immunol. 2003 Dec;4(12):1191-8
references.pmid: 14625547
references.citation: Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73
references.pmid: 12427970
references.citation: Mol Ther. 2009 May;17(5):880-8
references.pmid: 19259067
references.citation: J Clin Invest. 2008 Jan;118(1):294-305
references.pmid: 18060041
references.citation: Leukemia. 2004 Apr;18(4):676-84
references.pmid: 14961035
references.citation: J Immunol. 1998 Sep 15;161(6):2791-7
references.pmid: 9743337
references.citation: Blood. 2000 Jul 15;96(2):467-74
references.pmid: 10887107
references.citation: Blood. 2005 Jul 1;106(1):376-83
references.pmid: 15755898
references.citation: Mol Ther. 2005 Nov;12(5):933-41
references.pmid: 15979412
references.citation: Cancer Res. 2008 Apr 15;68(8):2961-71
references.pmid: 18413766
references.citation: Blood. 2006 Dec 1;108(12):3890-7
references.pmid: 16926291
references.citation: Mol Cell Biol. 1990 Aug;10(8):4239-42
references.pmid: 2370865
references.citation: Nat Immunol. 2000 Nov;1(5):426-32
references.pmid: 11062503
references.citation: J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66
references.pmid: 8028037
references.citation: N Engl J Med. 2003 Jan 16;348(3):255-6
references.pmid: 12529469
references.citation: Blood. 2009 Sep 17;114(12):2417-26
references.pmid: 19605850
references.citation: N Engl J Med. 1990 Aug 30;323(9):570-8
references.pmid: 2381442
references.citation: Immunol Rev. 2007 Feb;215:103-13
references.pmid: 17291282
references.citation: Cancer Res. 2007 Aug 1;67(15):7450-7
references.pmid: 17671215
references.citation: Blood. 2005 Jan 1;105(1):241-50
references.pmid: 15345595
references.citation: Nat Biotechnol. 2006 Jun;24(6):687-96
references.pmid: 16732270
references.citation: Mol Ther. 2007 Apr;15(4):825-33
references.pmid: 17299405
references.citation: Blood. 2001 May 15;97(10):3146-51
references.pmid: 11342442
references.citation: Cancer Res. 2007 Sep 1;67(17):8335-43
references.pmid: 17804749
references.citation: Cytotherapy. 2003;5(3):190-3
references.pmid: 12850996
references.citation: Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4
references.pmid: 8421711
references.citation: J Immunol. 2001 Dec 1;167(11):6356-65
references.pmid: 11714800
references.citation: Blood. 2007 Oct 1;110(7):2620-30
references.pmid: 17507664
references.citation: Science. 2006 Oct 6;314(5796):126-9
references.pmid: 16946036
references.citation: Blood. 2009 Jun 18;113(25):6392-402
references.pmid: 19377047
references.citation: Blood. 2003 Feb 15;101(4):1637-44
references.pmid: 12393484
references.citation: Nat Med. 1996 May;2(5):551-5
references.pmid: 8616714
references.citation: Blood. 2006 Mar 15;107(6):2409-14
references.pmid: 16304057
references.citation: J Clin Oncol. 2006 May 1;24(13):e20-2
references.pmid: 16648493
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5233-9
references.pmid: 18809613
references.citation: J Clin Oncol. 2005 Dec 10;23(35):8942-9
references.pmid: 16204009
references.citation: Lancet. 1995 Jan 7;345(8941):9-13
references.pmid: 7799740
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15
references.pmid: 17062687
references.citation: J Immunother. 1999 Nov;22(6):473-80
references.pmid: 10570745
references.citation: Blood. 2005 Mar 1;105(5):1898-904
references.pmid: 15542583
references.citation: Immunol Res. 2008;42(1-3):182-96
references.pmid: 18949448
references.citation: Mol Ther. 2008 Mar;16(3):599-606
references.pmid: 18227840
references.citation: Mol Ther. 2008 Mar;16(3):580-9
references.pmid: 18227839
references.citation: Science. 1995 Oct 20;270(5235):470-5
references.pmid: 7570000
references.citation: Cancer Res. 2007 Jun 15;67(12):5957-64
references.pmid: 17575166
references.citation: Nat Med. 2003 Apr;9(4):367-9
references.pmid: 12669036
references.citation: Int J Cancer. 2001 Oct 15;94(2):228-36
references.pmid: 11668503
references.citation: Blood. 2003 Jul 15;102(2):497-505
references.pmid: 12649146